Technology & innovation

This archive covers technology and innovation breakthroughs that improve lives, protect the environment, and expand human possibility. From medical devices to clean energy tools, the stories here focus on what’s working and who’s making it happen.

The China Zorrilla, a battery-electric catamaran ferry in Buquebus livery, on the water near Incat's shipyard

Argentina and Uruguay start service on world’s largest electric ferry

An electric ferry now shows that batteries can move thousands of people and hundreds of cars across a wide river estuary, not just small boats on short hops. The China Zorrilla, built by Australia’s Incat for the operator Buquebus, carries up to 2,100 passengers and 225 vehicles and recharges for about 40 minutes at each end of its 34-mile route. Its climate benefit depends on clean power, and range, energy use, and emissions savings have not been independently measured.

Depiction of melanoma cell

Melanoma vaccine cuts recurrence or death risk 42% in phase 3 trial

The melanoma vaccine is built from each patient’s own tumor, so no two doses are alike. Merck and Moderna’s therapy, called intismeran autogene, carries mRNA coding for up to 34 neoantigens, markers specific to a tumor, and is given with the immunotherapy Keytruda after surgery. In the phase 3 trial of 1,137 patients, two-year recurrence-free survival was 82.2% versus 70.0%. Overall survival data are not yet mature, and the therapy is not approved.

Illustration of a liver

U.S. FDA approves hepatitis B drug that offers some patients a functional cure

A hepatitis B drug used alongside existing antivirals is aimed at ending years of treatment for some adults, though most trial patients did not reach that result. In two placebo-controlled trials across 29 countries, 19% had no detectable virus or surface protein at least 24 weeks after stopping treatment, versus none on placebo. The label carries a boxed warning for liver flares and low platelets, excludes people with cirrhosis, and requires weekly blood checks.

Immunohistochemistry slide showing pancreatic cancer cells stained brown against pale tissue

U.S. FDA approves breakthrough pancreatic cancer drug that doubles survival

Pancreatic cancer has long been one of medicine’s most stubborn opponents, with a five-year survival rate of just 13 percent and few good options once chemotherapy stops working. The newly approved drug daraxonrasib offers patients a targeted second chance — blocking a specific protein that drives cancer cell growth rather than flooding the body with toxic agents. Clinical trial results showed a meaningful survival advantage over standard chemotherapy, though pricing remains unannounced and cost could limit who actually benefits. Still, the KRAS-targeting science behind this drug may eventually open new doors for other hard-to-treat cancers too.

Rows of cylindrical lithium-ion batteries, reflecting dramatic declines in global battery costs

Battery costs have declined by 99% worldwide over three decades

Battery storage — once the missing link in the clean energy transition — is finally arriving at scale, and the numbers behind it are hard to overstate. A learning curve built from millions of small improvements in chemistry and manufacturing has made what once seemed impossible feel routine. What was an extraordinary expense in 1991 now costs a fraction of that, pulling electric vehicles, home storage, and grid-scale power into reach for far more people. Supply chain pressures and raw material constraints mean progress isn’t guaranteed — but the direction, so far, is undeniable.

Two blue DNA double helix strands against a blurred orange background, symbolizing gene therapy

U.S. FDA approves first-ever gene therapy for inherited deafness, free to patients

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families.
In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within six months, and five regained normal hearing, including the ability to hear whispers. Instead of charging the millions per child that’s common for rare-disease therapies, Regeneron chose a different path. Beyond the families it directly helps, the decision hints at a quietly radical idea: that breakthrough medicine for rare conditions doesn’t have to come with a breathtaking price tag. Called Otarmeni, the one-time treatment uses two harmless viruses to deliver working copies of the OTOF gene deep into the inner ear, restoring otoferlin, the protein the cochlea needs to turn sound into signals the brain can read. Its maker, Regeneron, says it will offer the therapy free to patients in the U.S. Doctors who ran the trial described children responding to their parents’ voices, and to music, for the first time.
This particular genetic form of deafness is rare, affecting roughly 50 babies born in the U.S. each year. But researchers believe the breakthrough cracks open the door to gene therapies for many other inherited conditions worldwide.

Finger prick insulin injection

Once-weekly insulin wins U.S. approval, cutting 365 injections a year to 52

Once-weekly insulin just became reality in the U.S., dropping the routine for many adults with type 2 diabetes from 365 shots a year to about 52. The FDA approved Awiqli after four phase 3 trials, covering 2,680 adults, found it matched or outperformed daily basal insulin in lowering blood glucose. For people already taking a weekly GLP-1 medication, pairing the two could mean far fewer injection days and one less thing to remember. Doctors are urging thoughtful, individualized use, especially around hypoglycemia risk and affordability. Still, with more than 500 million adults living with diabetes worldwide, treatments that make daily life easier are a quietly powerful step forward for global health.

Child getting hearing test

U.S. FDA approves first gene therapy for inherited deafness, offered free to U.S. patients

Gene therapy can now restore hearing to children born deaf — and Regeneron is giving it away free to U.S. families. In a trial of 20 children with rare OTOF mutations, 16 gained meaningful hearing within about five months, and several were brought to essentially normal hearing. One toddler covered his ears when an ambulance siren passed — his first sign of sound. Instead of charging up to $4 million per child, as is common for rare-disease therapies, Regeneron chose a different path entirely. Beyond the families it directly helps, the decision hints at a quietly radical idea: that breakthrough medicine for rare conditions doesn’t have to come with a breathtaking price tag.

Cancer patient reading a book

Bowel cancer patients see zero relapses three years after new immunotherapy

Bowel cancer patients in a small U.K. trial saw zero relapses nearly three years after receiving immunotherapy before surgery — a striking result for all 32 participants, even those who still had traces of cancer after treatment. By comparison, the standard path of surgery followed by chemotherapy sees roughly one in four patients relapse within three years. The trial focused on people with a specific genetic profile that makes tumors more visible to the immune system, sparing them months of post-surgery chemo. One participant described the cancer “melting away” before his operation. If larger trials confirm the approach, it could reshape how a meaningful slice of bowel cancer cases are treated worldwide.

Two sets of hand holding newborn baby

W.H.O. approves world’s first malaria treatment for newborn babies

Newborn babies with malaria finally have a medicine made just for them. Coartem Baby, a cherry-flavored tablet that dissolves into breast milk or water, just earned World Health Organization prequalification — a green light that opens the door to public health systems across sub-Saharan Africa. For decades, doctors had to guess at doses using drugs built for older children, even as research showed infants were getting infected too. Ghana has already begun rolling it out, and Novartis has committed to what it calls “largely not-for-profit pricing” in malaria-endemic regions. Alongside new vaccines and better bed nets, it’s a quiet but meaningful sign that the fight against malaria — which still kills hundreds of thousands of children a year — is reaching the patients it had long overlooked.